A cell model for screening drugs with anti-chronic hypoxic lesion activity and its use and method of use

By constructing a cellular model of HIF-1α promoter and reporter gene, the problem of difficulty in screening active drugs against chronic hypoxia lesions in the prior art is solved, rapid and effective screening of drugs is achieved, and leading compounds for the development of new drugs and The basis of research on treatment mechanisms.

CN105695486BActive Publication Date: 2024-11-19SOUTHWEST JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201610064454.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2016-01-29
Publication Date
2024-11-19
Estimated Expiration
2036-01-29

AI Technical Summary

Technical Problem

Existing drug screening methods are difficult to quickly and effectively screen drugs with anti-chronic hypoxia lesions, especially in traditional Chinese medicine or new chemical entities, and there is a lack of effective screening models and methods.

Method used

A gene construct was constructed, including the HIF-1α promoter gene and reporter gene, which was used to construct recombinant vectors and transfect them into HEK293 cells, Hela cells or stem cells to form a stable cell model and detect reporter genes. Expression screening drugs that can increase the expression level of HIF-1α were selected.

Benefits of technology

It has realized the systematic and effective screening of drugs with anti-chronic hypoxia lesions, providing a multi-faceted screening model, which can quickly discover leading compounds for the development of new drugs and provide an early foundation for the treatment of neurofibrous lesions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN105695486B_ABST
    Figure CN105695486B_ABST
Patent Text Reader

Abstract

The present invention provides a cell model for screening drugs with anti-chronic hypoxic lesion activity, and its uses and use methods. The cell model constructed by the present invention takes the HIF-1ɑ promoter as a target, and can systematically, efficiently and comprehensively screen drugs with anti-chronic hypoxic lesion activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a cell model for screening drugs with anti-chronic hypoxic lesion activity, belonging to the field of medical biotechnology. Background Art

[0002] Chronic hypoxic lesions, such as chronic obstructive pulmonary disease, are diseases characterized by airflow limitation and are related to abnormal inflammatory responses of the lungs to harmful gases or particles such as cigarette smoke and chronic hypoxia. As the disease progresses, long-term chronic inflammation and hypoxia will induce hypoxic pulmonary vasoconstriction, pulmonary endothelial dysfunction and pulmonary vascular remodeling, which ultimately lead to the occurrence of pulmonary hypertension. Pulmonary vascular remodeling is closely related to the progression of the disease and its complications of pulmonary hypertension. The pathological changes mainly involve the coordination of oxygen changes in the body's cells at the gene transcription level, and the relevant functional gene is hypoxia inducible factor-1ɑ (HIF-1ɑ).

[0003] With the rapid development of life sciences, drug screening methods based on the detection of reporter genes have made great progress and been widely used in recent years. They involve intact cells and study the effects of drugs on the functions of living organisms under the natural conditions of living cells. They are closer to the biochemical processes in the body and can more accurately understand the biological properties of drugs.

[0004] The construction of a rapid and classified screening model for anti-chronic hypoxic lesion activity will not only help to find and discover effective drugs for the treatment of neurofibromatosis from traditional Chinese medicine or existing chemical drugs or new chemical entities, and provide new lead compounds for new drug research and development, but also provide a certain preliminary basis for the study of the mechanism of action of various drugs in the treatment of neurofibromatosis, which is beneficial to the modernization of traditional Chinese medicine.

[0005] Lu Qiong reported a drug screening model constructed based on the HIF-1ɑ promoter, but did not disclose the base sequence of the gene fragment used. Those skilled in the art had no way of knowing the specific structure and construction method of this screening model (Lu Qiong, Construction and application research of cell model for cerebral ischemia drug screening, Southwest Jiaotong University thesis, 2014). Summary of the invention

[0006] In order to construct a screening model for drugs with anti-chronic hypoxic lesion activity, the present invention provides a gene construct.

[0007] The gene construct provided by the invention contains, from the 5' end to the 3' end, the following sequence: a -583bp to +23bp sequence of a HIF-1α promoter gene and a reporter gene sequence.

[0008] Taking rat as an example, the sequence of -583bp to +23bp of HIF-1ɑ promoter gene is shown in SEQ NO.1:

[0009] Furthermore, the reporter gene is selected from: fluorescent protein gene and / or luciferase gene.

[0010] Preferably, the fluorescent protein gene is a green fluorescent protein (GFP) gene or a red fluorescent protein (RFP) gene; and the luciferase gene is a firefly luciferase gene.

[0011] Among red fluorescent proteins, E2-Crimson is the most commonly used.

[0012] The present invention further provides a recombinant vector, which contains the above gene construct.

[0013] The vector in the present invention refers to a self-replicating DNA molecule that transfers DNA fragments (target genes) to recipient cells in genetic engineering recombinant DNA technology, and commonly used ones include plasmids, bacteriophages, and animal and plant viruses.

[0014] The present invention further constructs a stable cell, which contains the above-mentioned recombinant vector or integrates the above-mentioned gene construct into its genome.

[0015] Furthermore, the cell is selected from any one of HEK293 cells, Hela cells, CHO cells or stem cells.

[0016] The present invention further provides a method for constructing the above-mentioned recombinant vector, which comprises the following steps:

[0017] (1) Synthesize the -583 bp to +23 bp sequence of the HIF-1ɑ promoter gene;

[0018] (2) The sequence synthesized in step (1) and the reporter vector with the reporter gene are respectively digested by enzymes, the reporter vector and the promoter fragment are connected, Escherichia coli is transformed, resistance screening is performed, positive transformants are selected, and plasmids are extracted to obtain the recombinant vector.

[0019] Furthermore, in step (2), the reporter vector is a pSC basic plasmid carrying a reporter gene.

[0020] The reporter gene described here is the same as above, that is, selected from fluorescent protein gene and / or luciferase gene.

[0021] The present invention further provides a method for constructing the above-mentioned stable cell, that is, transfecting the recombinant vector

[0022] Any of HEK293 cells, Hela cells, CHO cells or stem cells.

[0023] The present invention further provides the use of the stable cells, which can be used to screen drugs that can increase the expression level of HIF-1ɑ or have anti-chronic hypoxic lesion activity, such as various traditional Chinese medicines, existing chemical drugs, new chemical entities, etc.

[0024] The present invention further provides a method for screening drugs having anti-chronic hypoxic lesion activity, the method comprising the following steps:

[0025] (1) administering a candidate drug to the stable cells constructed by the present invention;

[0026] (2) detecting the expression of the reporter gene in the cells;

[0027] (3) Judging the result, if the candidate drug can increase the expression of the reporter gene, it indicates that the candidate drug can increase the expression level of HIF-1ɑ or has anti-chronic hypoxic lesion activity.

[0028] Further,

[0029] Step (1) comprises adding the candidate drug to the stable cell culture system constructed above for co-culturing;

[0030] Step (2) comprises detecting the expression of the reporter gene in the experimental group and comparing it with a blank control group, wherein the blank control group is the stable cells constructed by the present invention cultured under the same conditions as the experimental group without adding the candidate drug;

[0031] If the expression level of the reporter gene in the experimental group is higher than that in the control group, it indicates that the candidate drug can increase the expression level of HIF-1ɑ or has anti-chronic hypoxic lesion activity.

[0032] More preferably, if the expression level of the reporter gene in the experimental group / the expression level of the reporter gene in the control group is ≥150%, it indicates that the candidate drug has anti-chronic hypoxic lesion activity.

[0033] The present invention constructs a cell screening model with HIF-1ɑ promoter as a target, which can systematically, effectively and comprehensively screen drugs with anti-chronic hypoxic lesion activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 Schematic diagram of plasmid construction

[0035] Figure 2 Construction of monoclonal cell lines (fluorescence field and bright field, 200×)

[0036] Figure 3 The constructed stable 293-pHp-E2 cell line (fluorescence field, 100×)

[0037] Figure 4Functional identification of red fluorescent protein (E2) cell model (fluorescence field, 100×),

[0038] A: 293-pHp-E2 (0μM CoCl2); B: 293-pHp-E2 (300μM CoCl2)

[0039] Figure 5 Functional identification of luciferase cell model (293-pHp-Luc)

[0040] Figure 6 Screening results of 5 Chinese herbal medicine extracts. DETAILED DESCRIPTION

[0041] Material

[0042] 1.1 Strains and cell lines Escherichia coli strain DH5α (deposited in Laboratory 505, National Biomedical Materials Engineering Research Center, Sichuan University) and human embryonic kidney epithelial cells HEK293 (deposited in Laboratory 505, National Biomedical Materials Engineering Research Center, Sichuan University).

[0043] 1.2 Plasmid pSC-E2, i.e., pSC plasmid (constructed in 505 laboratory) connected with reporter gene E2-Crimson (E2) (red fluorescent protein), and pSC-Luc, i.e., pSC plasmid (constructed in 505 laboratory) connected with reporter gene Luciferase (Luc) (luciferase) (construction method see S Liu, L Ma, R Tan, et al. Safe and efficient local gene delivery into skeletal muscle via a combination of Pluronic L64 and modified electrotransfer. Gene Therapy (2014) 21, 558–565).

[0044] 1.3 Main reagents LA Taq polymerase (TaKaRa), Pfu DNA polymerase (Fermentas), Taq polymerase (Invitrogen); restriction endonucleases (Fermentas): MluⅠ, AflⅡ, MunⅠ, BamHI, NotⅠ, HindⅢ, XbaⅠ; T4 DNA ligase (TaKaRa); EZNA TM Plasmid miniprep kit (EZNA TMPlasmid Mini Kit I, Omega), gel recovery kit (BioSpin Gel Extraction Kit, Bioflux); mammalian cell transfection reagent (Lipofectamine TM 2000, Invitrogen), luciferase assay kit (Luciferase Assay System with Reporter Lysis Buffer, Promega), protein concentration assay kit ( BCA Protein Assay Kit (Thermo), G418 (Amresco), dimethyl sulfoxide (DMSO, Sigma), cobalt dichloride (CoCl2, Sigma), cell culture dishes (Thermo), and various specifications of culture plates (Corning). All other chemical reagents were of domestic analytical grade unless otherwise specified.

[0045] 1.4 Instrument PCR instrument (S1000 TM Thermal Cycler, BIO-RAD), electrophoresis instrument (DYY-Ⅲ, Beijing Liuyi Instrument Factory), gel imaging analysis system (ChemiDoc XRS+, BIO-RAD), ultra-micro spectrophotometer (Nanodrop2000, Thermo Scientific), microscope (DMIL, Leica), inverted phase-contrast fluorescence microscope (DMI4000B, Leica), CO2 incubator (MACO-15AC, SANYO), clean bench (SW-CJ-2N, Harbin Donglian Company), microplate reader ( Flash, Thermo Scientific).

[0046] Example 1 Construction of recombinant plasmid

[0047] 1.1 Test methods

[0048] Using rat genomic DNA as a template, primers were designed to introduce MluⅠ and AflⅡ restriction sites upstream and downstream of the rHIF-1ɑ promoter sequence for PCR amplification to obtain the promoter fragment: rHIF-1ɑpro (abbreviated as Hp) (-583bp~+23bp) (+1 is the gene transcription start site), the sequence of the forward primer is shown in SEQ NO.2, and the sequence of the reverse primer is shown in SEQ NO.3. 1% agarose gel electrophoresis was used to identify, and each promoter fragment was recovered by ethanol precipitation. The vector pSC-E2 and each promoter fragment (Hp) were double-digested, 1% agarose gel electrophoresis was performed, the target fragment was recovered by gel, the vector and the promoter fragment were connected, Escherichia coli were transformed, ampicillin plate resistance screening was performed, positive transformants were selected, and rapid lysis identification was performed. After the positive ones were expanded and cultured, the plasmids were extracted, and restriction digestion and PCR identification were performed. The successfully identified plasmids were sequenced, and finally the recombinant plasmid pHp-E2 was obtained.

[0049] The recombinant plasmid pHp-Luc was prepared in the same way.

[0050] 1.2 Experimental Results

[0051] like Figure 1 As shown in the schematic diagram, two reporter gene systems were constructed in this study, in which the reporter gene E2 is a red fluorescent protein for rapid qualitative observation and judgment; Luc is a luciferase for quantitative determination. The results of double enzyme digestion and PCR identification showed that the recombinant plasmid was successfully constructed. It was sent to Shanghai Biotech Co., Ltd. for sequencing. The sequencing results showed that the inserted promoter sequences were consistent with those included in NCBI, indicating that the recombinant plasmids pHp-E2 and pHp-Luc were successfully constructed.

[0052] Example 2 Establishment of stable cell lines

[0053] 2.1 Experimental methods

[0054] Transfect HEK293 cells with recombinant plasmids pHp-E2 and pHp-Luc, respectively. For details, see Lipofectamine TM2000 reagent instructions. After the cells were digested with trypsin 36 to 48 hours after transfection, they were dispersed and cultured in 10 cm culture dishes in appropriate amounts according to the transfection efficiency. After the cells adhered to the wall, 800 ng / μL G418 was used for screening. After 2-3 weeks, the cells formed separate colonies with a large distance between them in the culture dish. The appropriate cell colonies were selected under an inverted microscope, and the positions of the cell colonies were marked on the bottom of the culture dish with a marker. In a strictly aseptic operation, a 1 mL pipette tip was cut into an appropriate bevel with a surgical blade, and all cells around the marked point were carefully removed with a beveled pipette tip. The scraped cells were rinsed and removed as much as possible with culture medium, and the marked cells were retained and cultured with fresh culture medium. When the selected cell colony gradually expanded, the surrounding miscellaneous cells were detected in real time and removed in time. When the cell colony grew to an appropriate size, it was digested with trypsin and graded diluted into a 96-well plate. After the cells adhered to the wall, the wells containing single cells were selected under a fluorescence microscope, marked, and focused on detection and culture. When the cells grew into clones of appropriate size in the 96-well plate, they were transferred to a 24-well plate for expansion culture, and then transferred to a 6-well plate for expansion culture and frozen in time.

[0055] 2.2 Experimental Results

[0056] like Figure 2 As shown, the fluorescence field and bright field observation results show the construction process of the stably transfected monoclonal cell line, and it can be seen that the monoclone gradually grows.

[0057] Figure 3 It is also shown that the present invention constructs HEK-293 cells stably transfected with pHp-E2 (abbreviated as 293-pHp-E2 cells).

[0058] Example 3 Functional identification of cell models

[0059] 3.1 Experimental methods

[0060] The positive stimulus CoCl2 can upregulate the expression of HIF-1ɑ in cells, so it can be used to verify whether the screening model is successfully established. If the screening model is successfully established, the expression of HIF-1ɑ in cells will be upregulated after stimulation with the positive stimulus.

[0061] To verify the effectiveness of the model, the responses of two reporter gene cell models, 293-pHp-E2 cells and 293-pHp-Luc cells, to known positive stimuli were examined.

[0062] The culture conditions of HEK-293 cells were adopted for the culture of 293-pHp-E2 cells, 293-pHp-Luc cells and HEK-293 cells, i.e., DMEM high-glucose culture medium (Hyclone) + 10% FBS (Sciencell) + 1×105 U / L penicillin and streptomycin (Hyclone) were added and cultured in a 37°C, 5% CO2 incubator. The cell number and morphology were observed every day. When the cells grew to 80% confluence, they were digested and passaged with 0.25% trypsin (Hyclone) or inoculated into 24-well or 96-well plates according to experimental needs. Cells in the logarithmic growth phase were used for experiments.

[0063] The experiment set up a blank control group and an experimental group, with 3 replicates for each concentration. CoCl2 was diluted with culture medium to a solution of corresponding concentration. The experimental group was added with positive stimuli as follows, and the blank control group was added with the corresponding volume of culture medium. The final working concentrations of CoCl2 in the experimental group were 0, 50μM, 150μM, and 300μM, and the treatment time was 24h.

[0064] The response of 293-pHp-E2 cells to positive stimuli was directly observed using a fluorescence microscope; the response of 293-pHp-Luc cells to positive stimuli was detected using a luciferase detection kit.

[0065] The steps for luciferase activity detection are as follows:

[0066] Dilute Reporter Lysis 5×Buffer to Lysis 1×Buffer, collect cells in the well plate with Lysis 1×Buffer, place in 0.5mL EP tube, and store at -80℃ overnight for later use. Take out the 293-pHp-Luc cells frozen at -80℃ in the experimental group and the control group, place at 4℃ to thaw, vortex on a vortexer for 15s after complete thawing, and centrifuge at 4℃, 12000×g for 3min to obtain the supernatant. Accurately pipette 20μL supernatant into a white microplate, with 3 parallels for each sample. Set 50μL LuciferaseAssay Substrate per well for automatic injection. Measure the activity of luciferase with an enzyme marker.

[0067] The protein concentration was determined using a protein concentration assay kit ( BCA Protein Assay Kit, Thermo) was used to determine the protein content. First, prepare the standard curve solution according to the kit instructions. Then accurately pipette 25 μL of standard solution or sample supernatant into a 96-well plate, with 3 parallels for each sample, add 200 μL of working solution (working regent) to each well, shake gently, incubate at 37°C for 30 minutes, cool to room temperature, and measure the absorbance value at 562nm with an enzyme marker. Draw a standard curve with BSA content as the horizontal axis and absorbance value as the vertical axis. Calculate the protein content of the sample according to the standard curve equation.

[0068] The final luciferase activity is: relative luciferase activity unit = luciferase activity / protein content.

[0069] 3.2 Experimental Results

[0070] like Figure 4 As shown, after 24 hours of treatment, the red color of the 300 μM CoCl2-treated group gradually brightened with time, that is, the expression of red fluorescent protein gradually increased, the brightness of the control group was almost negligible, and the brightness of the CoCl2-treated group was significantly higher than that of the blank control group. This shows that the present invention successfully constructed 293-pHp-E2 cells, and the cell model can respond to positive stimuli.

[0071] like Figure 5 As shown, the expression of luciferase increases with the increase of the concentration of positive stimuli, and the difference at high doses compared with the untreated blank group is statistically significant (P<0.05). This shows that the present invention successfully constructs 293-pHp-Luc cells, and the cell model can respond to positive stimuli.

[0072] Example 4: The cell model of the present invention is used for drug screening

[0073] 4.1 Experimental methods

[0074] The 17 monomer components extracted and separated from traditional Chinese medicine were numbered 1 to 17. The activity of the 5 monomer components was screened using the constructed 293-pHp-Luc cell model, with a screening concentration of 1 μM and a treatment time of 24 h. The specific experimental steps refer to Example 3.

[0075] The luciferase activity of each group of cells treated with drugs was determined according to the above-mentioned luciferase activity determination method. Compared with the negative solvent control group, the effect of each monomer component on the transcriptional activity of the HIF-1ɑ gene was calculated, and the upregulation change rate ≥ 150% was used as the screening activity judgment standard.

[0076] Up-regulation change rate = (relative luciferase activity of the experimental group / relative luciferase activity of the control group) × 100%.

[0077] 4.2 Experimental Results

[0078] like Figure 6 As shown, among the 17 monomer components extracted from traditional Chinese medicine, the up-regulation change rate of 7 monomer components in the treatment group was greater than 150%, which was screening positive, indicating that these 7 monomer components may have good anti-chronic hypoxic lesion activity.

[0079] These 7 components are 1 (astragaloside IV, C 41 H 68 O 14 )、3(peony root glycoside, C 23H 28 O 11 ), 4(eugenol, C 10 H 12 O2), 7(hydroxysafflor yellow, C 27 H 32 O 16 )、9(genkwain, C 16 H 12 O5), 11(Salidroside, C 14 H 20 O7), 12(mangiferin, C 19 H 18 O 11 ).

[0080] In summary, the present invention constructs a cell screening model with HIF-1ɑ promoter as the target, which can systematically, effectively and comprehensively screen drugs with anti-chronic hypoxic lesion activity. SEQUENCE LISTING <110> Southwest Jiaotong University <120> A cell model for screening drugs with anti-chronic hypoxic lesion activity and its use and method of use <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 606 <212> DNA <213> Rat HIF promoter fragment nucleotide sequence <400> 1 gcacccgtcggtcgcccctttctcttctctccctagctgcacacagacgagcacgtgagc 60 tgggcagctcgccccagctggggctcagctgacctcctcctgattggctgagagcaacgt 120 gggctggggtggggcctggccgcctgcgtcctttcccattggctctcggggaacccgcct 180 ccgctcaggtgaggcgggcccgcgggtgcgcgcgtcgggcttagcgggcgcgcgcagccc 240 tttgctcccctcccctcgccgcgcgcccgagcgcgcctccgcccttgcccgccccctgcc 300 gctgcctcagcgcctcagtgcacagaggctcctcgtctgaggggacgcgaggactgtcct 360 cgctaccgtcgcgagcagtgtctggccaggccttgacaagccagccggaggagcaactag 420 gaacccgaaccagagcccggcgagcgcagcctgcagctcccgcctcgccgtcccgggggg 480 gtgtcccgcctcacaccccgcctctggacttgcccctttctctgcgcgtgaggacagagc 540 cggcgcttaggccggagcgagcccaggggctgccggccgggaagacaccgcgggcaccga 600 ttcgcc 606 <210>2 <211>28 <212>DNA <213>Forward primer for amplifying HIF-1α promoter fragment <400>2 acgcgtgcacccgtcggtcgcccctttc 28 <210>3 <211>28 <212>DNA <213>Reverse primer for amplifying HIF-1α promoter fragment <400>3 cttaagggcgaatcggtgcccgcggtgt 28

Claims

1. A stable cell, characterized in that: The cell contains the following recombinant vector: the recombinant vector contains the following gene constructs: the gene constructs contain, from the 5' end to the 3' end: a HIF-1a promoter gene -583 bp to +23 bp sequence and a reporter gene sequence; the HIF-1a promoter gene -583 bp to +23 bp sequence is as shown in SEQ NO.1, the reporter gene is a luciferase gene, and the cell is a HEK293 cell.

2. The cell according to claim 1, characterized in that: The luciferase gene is a firefly luciferase gene.

3. Use of the stable cells according to claim 1 or 2 in screening drugs that increase the expression level of HIF-1a or have anti-chronic hypoxic activity.

4. A method for screening a drug that increases the expression level of HIF-1a or has anti-chronic hypoxic lesion activity, characterized in that: The method comprises the following steps: (1) administering a candidate drug to the stable cell according to claim 1 or 2; (2) detecting the expression of a reporter gene in the cells, including detecting the expression of the reporter gene in the experimental group and comparing it with a blank control group, wherein the blank control group is the cells of claim 1 or 2 cultured under the same conditions as the experimental group without adding the candidate drug; (3) Judgment results: if the expression level of the reporter gene in the experimental group / the expression level of the reporter gene in the control group is ≥150%, it indicates that the candidate drug can increase the expression level of HIF-1a or has anti-chronic hypoxic activity.

5. The method according to claim 4, characterized in that Step (1) comprises adding the candidate drug to the stable cell culture system of claim 1 or 2 for co-culturing.